REGN vs SMMT
REGN: Regeneron is a leading biotechnology firm that leverages its human genetics research and proprietary technology to discover and commercialize innovative therapies for serious diseases. SMMT: A biopharmaceutical company dedicated to the clinical advancement of its lead bispecific antibody, ivonescimab, for oncology applications.
Side-by-side fundamentals
| Metric | REGN | SMMT | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $667.17 | $13.10 | |
| Market cap as of 2026-08-01 | $62.7B | $10.2B | |
| P/E as of 2026-08-01 | 17.49 | n/a | |
| PEG as of 2026-08-01 | 1.08 | -1.08 | SMMT lower |
| Net margin as of 2026-08-01 | +29.6% | -9027.1% | REGN higher |
| Gross margin as of 2026-08-01 | +85.7% | n/a | |
| Operating margin as of 2026-08-01 | +24.3% | -8108.3% | REGN higher |
| ROE as of 2026-08-01 | +14.3% | -168.9% | REGN higher |
| ROA as of 2026-08-01 | +11.1% | -141.9% | REGN higher |
| Debt / equity as of 2026-08-01 | 0.09 | 0.00 | SMMT lower |
| Revenue growth (YoY) as of 2026-08-01 | +5.9% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +5.6% | n/a | |
| Dividend yield as of 2026-08-01 | +0.5% | n/a | |
| Beta as of 2026-08-01 | 0.19 | -1.33 | |
| 1-year return as of 2026-07-27 close | +18.5% | -54.3% | REGN higher |
Fundamentals: market data, as of 2026-08-01. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.